Healthcare / Health Information ServicesTokyo
$1353.00
-7.00 (-0.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $971.4M · quality 66.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$36.2B
P/E
57.5x
↑EV/EBITDA
25.3x
↑ROE
9.1%
↑Gross Margin
28.9%
↓Debt/Equity
0.74
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.7%
FCF CAGR
-21.2%
FCF margin
7.6%
FCF / Net income
1.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.07B · net income $629.0M · FCF $762.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.07B | $10.07B | $8.38B | $7.10B | $6.17B |
| Net Income | $629.0M | $629.0M | $791.1M | $970.0M | $880.8M |
| EBITDA | $1.43B | $1.43B | $1.55B | $1.84B | $1.67B |
| EPS | — | — | 29.53 | 36.99 | 33.49 |
| Gross Margin | 28.9% | 28.9% | 34.9% | 41.4% | 41.8% |
| Operating Margin | 8.8% | 8.8% | 13.3% | 19.5% | 19.4% |
| Net Margin | 6.2% | 6.2% | 9.4% | 13.7% | 14.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.74 | 0.74 | 0.84 | 0.97 | 1.18 |
| Current Ratio | 0.97 | 0.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $762.3M | $762.3M | $1.48B | $971.4M | $1.56B |
| Returns | |||||
| ROE | 9.1% | 9.1% | 11.8% | 15.4% | 15.6% |
| Valuation | |||||
| P/E | 57.50 | 57.50 | 57.09 | 40.31 | 42.28 |
| EV/EBITDA | 25.34 | 25.34 | 29.23 | 21.69 | 23.26 |
| P/B | 5.24 | 5.24 | 6.75 | 6.19 | 6.60 |
| Growth & Yield | |||||
| Revenue Growth | 20.2% | 20.2% | 18.0% | 15.1% | — |
| EPS Growth | — | — | -20.2% | 10.5% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.3%
Start / end P/E
n/dx → n/dx
EPS bridge
29.53 → n/d
Residual
-12.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.